Our top pick for
Theratechnologies Inc is a drug manufacturers-specialty & generic business based in the US. Theratechnologies shares (THTX) are listed on the NASDAQ and all prices are listed in US Dollars. Theratechnologies employs 42 staff and has a trailing 12-month revenue of around USD$63.3 million.
|Latest market close||USD$2.27|
|52-week range||USD$1.33 - USD$3.32|
|50-day moving average||USD$2.1917|
|200-day moving average||USD$2.2581|
|Wall St. target price||N/A|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.2921|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-06)||N/A|
|1 month (2020-12-13)||N/A|
|3 months (2020-10-13)||N/A|
|6 months (2020-07-13)||N/A|
|1 year (2020-01-13)||N/A|
|2 years (2019-01-13)||N/A|
|3 years (2018-01-13)||N/A|
|5 years (2016-01-13)||N/A|
Valuing Theratechnologies stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Theratechnologies's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Theratechnologies's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$4.3 million.
The EBITDA is a measure of a Theratechnologies's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$63.3 million|
|Gross profit TTM||USD$31.2 million|
|Return on assets TTM||-11.48%|
|Return on equity TTM||-122.31%|
|Market capitalisation||USD$176.6 million|
TTM: trailing 12 months
There are currently 1.8 million Theratechnologies shares held short by investors – that's known as Theratechnologies's "short interest". This figure is 6.6% up from 1.7 million last month.
There are a few different ways that this level of interest in shorting Theratechnologies shares can be evaluated.
Theratechnologies's "short interest ratio" (SIR) is the quantity of Theratechnologies shares currently shorted divided by the average quantity of Theratechnologies shares traded daily (recently around 87099.90521327). Theratechnologies's SIR currently stands at 21.1. In other words for every 100,000 Theratechnologies shares traded daily on the market, roughly 21100 shares are currently held short.
However Theratechnologies's short interest can also be evaluated against the total number of Theratechnologies shares, or, against the total number of tradable Theratechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Theratechnologies's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Theratechnologies shares in existence, roughly 20 shares are currently held short) or 0.0241% of the tradable shares (for every 100,000 tradable Theratechnologies shares, roughly 24 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Theratechnologies.
Find out more about how you can short Theratechnologies stock.
We're not expecting Theratechnologies to pay a dividend over the next 12 months.
Over the last 12 months, Theratechnologies's shares have ranged in value from as little as $1.33 up to $3.32. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Theratechnologies's is 1.6771. This would suggest that Theratechnologies's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Theratechnologies Inc., a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. It offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. The company's pipeline products include F8 Formulation that could be used for the treatment of HIV-associated lipodystrophy; TH-1902 for the treatment of triple negative breast cancer; and TH-1904 for the treatment of ovarian cancer. The company was founded in 1993 and is headquartered in Montreal, Canada.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.